truxima

October 24, 2019October 24, 2019

Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo

News

A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial ... Read more

December 14, 2018

Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma

News

Truxima (rituximab-abbs), a biosimilar to Rituxan (rituxumab), has similar safety and efficacy as the original product in patients with advanced follicular lymphoma after two years, results from a Phase 3 ... Read more

October 15, 2018

FDA Committee Recommends Truxima’s Approval for 3 Non-Hodgkin’s Lymphoma Indications

News

Truxima (CT-P10) a biosimilar to Rituxan (rituximab), has been unanimously recommended for approval by the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee for the treatment of three non-Hodgkin’s lymphoma (NHL) indications, ... Read more

June 23, 2017June 23, 2017

Truxima Shows Similar Safety and Efficacy Results to Rituxan in Phase 3 Trial

News

Results from a Phase 3 trial have shown that Truxima (CT-P10), developed by Celltrion Healthcare, has a similar efficacy and safety profile as Genetech’s Rituxan (rituximab) for the treatment of advanced-stage follicular lymphoma. ... Read more

February 28, 2017

European Union OKs Truxima as Biosimilar to Rituximab to Treat Lymphoma, Other Diseases

News

The European Union has approved Celltrion Healthcare’s biosimilar Truxima to treat the same conditions as rituximab, the therapy on which Truxima is based. The European Commission’s sign-off means Truxima (CT-P10) can ... Read more